Loading
Life sciences · Journal article
Ukrainian Journal of Pediatric Endocrinology · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective — to determine the role of the rs1800795 (-174G/C) polymorphism of the interleukin-6 (IL-6) gene in the development of clinical and metabolic manifestations of hypothalamic dysfunction (HD) in children and adolescents. Materials and methods. Genotyping was performed in 40 children (aged (14.97 ± 2.07) years) from the Ukrainian population with HD and obesity. The rs1800795 (-174G/C) polymorphism of the IL-6 gene was determined using polymerase chain reaction, restriction fragment length polymorphism (PCR-RFLP) analysis followed by agarose gel electrophoresis. Results and discussion. The obtained results indicate the involvement of the IL-6 gene polymorphism rs1800795 (-174G/C) — specifically its G allele — in the development of clinical and metabolic manifestations of HD in children and adolescents, primarily obesity, insulin resistance (IR), atherosclerotic changes, carbohydrate metabolism disorders, and metabolic dysfunctionassociated steatotic liver disease (MASLD). The presence of the G allele in both heterozygous (C/G) and homozygous (G/G) states was associated with the progression of obesity, IR, increased glycated hemoglobin levels, elevated markers of atherogenic dyslipidemia, and increased aspartate aminotransferase and alanine aminotransferase activity; this points to liver tissue involvement (development of MASLD) against the background of neuroendocrine disorders. For the first time, a pronounced inverse correlation was identified between the presence of the G allele and serum 25(OH)D levels. Geographic and racial differences may influence the association between IL-6 gene polymorphisms and endocrine disorders, explaining the inconsistent effects of these polymorphisms and their role in disease development across different populations. Conclusions. The presence of the G allele (especially in the homozygous G/G state) in patients with hypothalamic pathology is associated with a deterioration of key metabolic parameters. A distinct allelespecific effect is observed: an increase in body weight, progression of insulin resistance, development of atherogenic dyslipidemia, elevation of liver cytolysis markers, and worsening vitamin D deficiency; this indicates the significant pathogenetic role of this polymorphism in the development of metabolic syndrome associated with hypothalamic pathology.